depression relief within 24 hours.
In the first controlled study of this method of medication administration, investigators found the drug to be well-tolerated in patients with treatment-resistant major depressive disorder.
Researchers from the Icahn School of Medicine at Mount Sinai in New York have published their findings online in the peer-reviewed journal Biological Psychiatry.
Investigators found that among the 18 patients completing two treatment days with ketamine or saline, eight met response criteria to ketamine within 24 hours versus one on saline. Ketamine proved safe with minimal dissociative effects or changes in blood pressure.
The study randomized 20 patients with major depressive disorder to ketamine (a single 50 mg dose) or saline in a double-blind, crossover study.
Change in depression severity was measured using the Montgomery-Asberg Depression Rating Scale. Secondary outcomes included the durability of response, changes in self-reports of depression, anxiety, and the proportion of responders.
“One of the primary effects of ketamine in the brain is to block the NMDA [N-methyl-d-aspartate] glutamate receptor,” said James W. Murrough, M.D.
“There is an urgent clinical need for new treatments for depression with novel mechanisms of action. With further research and development, this could lay the groundwork for using NMDA targeted treatments for major depressive disorder.”
“We found intranasal ketamine to be well-tolerated with few side effects,” said psychiatrist and researcher Kyle Lapidus, M.D., Ph.D.
One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years.
However, ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused.
Nevertheless, in low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
Anne and Joel Ehrenkranz comment:
“What we have here is a proof of concept study and we consider the results very promising,” said co-author Dennis S. Charney, M.D. “We hope to see this line of research further developed so that we have more treatments to offer patients with severe, difficult-to-treat major depressive disorder.”
The Mount Sinai research team hopes to examine the mechanism of action, dose ranging, and use functional brain imaging to further elucidate how ketamine works.